A Phase 2 interventional study of Lifileucel in Metastatic Melanoma, sponsored by Iovance Biotherapeutics, Inc.. Completed at 57 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lifileucel in Melanoma — 4 open to participants now, 7 under way, 1 of them phase 3. lifileucel · Melanoma.
Among the 13 studies testing lifileucel in Melanoma, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 1st registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →4 of the 13 studies testing lifileucel in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
Iovance Biotherapeutics, Inc. · Sites in United States, Australia, Belgium and 13 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Vastra Gotaland Region
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
lifileucel: first FDA approval 2024 (AMTAGVI). What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 10 across the 13 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 8 most frequent:
Iovance Biotherapeutics, Inc. is the lead sponsor of 16 studies on the registry; 8 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Iovance Biotherapeutics, Inc. has 8 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing lifileucel in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05607095Memorial Sloan Kettering Cancer CenterA Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | 2027-05-01 |
| NCT05640193Memorial Sloan Kettering Cancer CenterA Study of LN-144 in People With Metastatic Melanoma to the Brain | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing lifileucel in Melanoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.
Lifileucel is an autologous adoptive cell transfer therapy that utilizes a TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with metastatic melanoma. The adoptive cell transfer therapy used in this study involves patients receiving a lymphocyte depleting preconditioning regimen, prior to infusion of autologous TIL, followed by the administration of a regimen of IL-2.
Patients must meet all of the following inclusion criteria to be eligible for participation in the study:
Criteria for Inclusion:
At least one measurable target lesion, as defined by v1.1
Patients must have the following hematologic parameters:
Patients must have adequate organ function:
Patients must have recovered from all prior therapy-related adverse events (AEs) to ≤ Grade 1 (per [CTCAE] v4.03), except for alopecia or vitiligo, prior to Enrollment (tumor resection)
Patients must have a ≥ 28 days from prior anticancer therapy(ies) to the start of the planned NMA-LD preconditioning regimen:
Patients of or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the study and practice an approved, highly effective method of during treatment and for 12 months after receiving the last protocol-related therapy
Criteria for Exclusion:
Patients who meet any of the following criteria are not eligible for participation in this study:
Patients who have a history of to any component or of LN-144 or other study drugs:
Patients with symptomatic and/or untreated (of any size and any number)
Patients who have a (LVEF) \< 45% or (NYHA) functional classification > Class 1
Patients protected by the following constraints:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)
Biological: Lifileucel
Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
Biological: Lifileucel
Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
Biological: Lifileucel
Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
Biological: Lifileucel
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.
Also known as: LN - 144
Disease Assessment for Objective Response Rate
Evaluate the efficacy of LN-144 in patients with unresectable or metastatic melanoma using the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for Cohorts 1 \& 3 and as assessed by Independent Review Committee (IRC) per RECIST Version 1.1 for Cohorts 2 \& 4
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Disease Assessment for Duration of Response
Evaluate the efficacy endpoints of duration of response (DOR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Disease Assessment for Disease Control Rate
Evaluate the efficacy endpoints of disease control rate (DCR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Disease Assessment for Progression-Free Survival
Evaluate the efficacy endpoints of Progression-Free Survival by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Overall Survival
Evaluate overall survival (OS)
Time frame: Until death or up to 60 months
Safety Profile
Incidence, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events
Time frame: Maximum 60 months
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 31 | 78 | 0 | 111 |
| Patients infused with til | 23 | 67 | 0 | 89 |
| Completed | 0 | 14 | 0 | 14 |
| Not completed | 31 | 64 | 0 | 97 |
| Withdrew: Death | 16 | 49 | 0 | 71 |
| Withdrew: Lost to follow-up | 0 | 4 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Other | 7 | 0 | 0 | 0 |
| Withdrew: Did not receive til | 8 | 11 | 0 | 22 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 0 | 0 | 12 | 0 |
| Completed | 0 | 0 | 1 | 0 |
| Not completed | 0 | 0 | 11 | 0 |
| Withdrew: Death | 0 | 0 | 11 | 0 |
Evaluate the efficacy of LN-144 in patients with unresectable or metastatic melanoma using the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for Cohorts 1 \& 3 and as assessed by Independent Review Committee (IRC) per RECIST Version 1.1 for Cohorts 2 \& 4
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Disease Assessment for Objective Response Rate | 4 | 23 | 1 | 25 |
Evaluate the efficacy endpoints of duration of response (DOR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
| months | Cohort 2 | Cohort 4 | Cohort 1 |
|---|---|---|---|
| Disease Assessment for Duration of Response | NA (NA to NA) | 10.4 (4.1 to 26.2) | NA (3.0 to NA) |
Evaluate the efficacy endpoints of disease control rate (DCR) by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
| Participants | Cohort 2 | Cohort 4 | Cohort 1 |
|---|---|---|---|
| Disease Assessment for Disease Control Rate | 48 | 72 | 12 |
Evaluate the efficacy endpoints of Progression-Free Survival by the IRC for Cohorts 2 \& 4 and by the investigator for Cohort 1 per RECIST v1.1
| months | Cohort 2 | Cohort 4 | Cohort 1 |
|---|---|---|---|
| Disease Assessment for Progression-Free Survival | 4.1 (2.8 to 8.4) | 3.9 (2.8 to 4.9) | 2.6 (1.4 to 4.2) |
Evaluate overall survival (OS)
| months | Cohort 2 | Cohort 4 | Cohort 1 |
|---|---|---|---|
| Overall Survival | 15.6 (11.0 to 23.3) | 12.7 (8.3 to 17.8) | 12.9 (5.3 to 26.1) |
Incidence, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| TEAE-Any Grade | 23 | 67 | 12 | 89 |
| TEAE-Grade 3/4 | 23 | 65 | 12 | 86 |
| TEAE-Grade 5 | 0 | 2 | 0 | 2 |
| TEAE Related to LN-144- Any Grade | 16 | 50 | 8 | 70 |
| TEAE Related to LN-144-Grade 3/4 | 10 | 28 | 3 | 32 |
| TEAE Related to LN-144-Grade 5 | 0 | 1 | 0 | 0 |
| TEAE leading to LN-144 discontinuation -Any Grade | 0 | 2 | 0 | 0 |
| TEAE leading to LN-144 discontinuation- Grade 3/4 | 0 | 2 | 0 | 0 |
| TEAE leading to LN-144 discontinuation-Grade 5 | 0 | 0 | 0 | 0 |
| Treatment-Emergent SAE- Any Grade | 9 | 23 | 2 | 31 |
| Treatment-Emergent SAE- Grade 3/4 | 9 | 22 | 2 | 29 |
| Treatment-Emergent SAE- Grade 5 | 0 | 2 | 0 | 2 |
| Treatment-Emergent SAE related to LN-144-Any Grade | 2 | 6 | 0 | 2 |
| Treatment-Emergent SAE related to LN-144-Grade 3/4 | 2 | 5 | 0 | 1 |
| Treatment-Emergent SAE related to LN-144-Grade 5 | 0 | 1 | 0 | 0 |
Collected over From enrollment to end of follow-up (up to 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 18/23 (78.3%) | 9/23 (39.1%) | 23/23 (100%) |
| Cohort 2 | 49/67 (73.1%) | 23/67 (34.3%) | 67/67 (100%) |
| Cohort 3 | 11/12 (91.7%) | 2/12 (16.7%) | 12/12 (100%) |
| Cohort 4 | 71/89 (79.8%) | 31/89 (34.8%) | 89/89 (100%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Thrombocytopenia [2]Blood and lymphatic system disorders | 3/23 | 4/67 | 2/12 | 3/89 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/23 | 6/67 | 0/12 | 2/89 |
| Neutropenia [1]Blood and lymphatic system disorders | 1/23 | 1/67 | 1/12 | 2/89 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/23 | 0/67 | 1/12 | 1/89 |
| NauseaGastrointestinal disorders | 1/23 | 0/67 | 0/12 | 0/89 |
| VomitingGastrointestinal disorders | 1/23 | 0/67 | 0/12 | 0/89 |
| PyrexiaGeneral disorders | 1/23 | 2/67 | 0/12 | 1/89 |
| Systemic inflammatory response syndromeGeneral disorders | 1/23 | 0/67 | 0/12 | 0/89 |
| Viral infectionInfections and infestations | 1/23 | 0/67 | 0/12 | 0/89 |
| Blood bilirubin increasedInvestigations | 1/23 | 0/67 | 0/12 | 0/89 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 18/23 | 46/67 | 11/12 | 54/89 |
| Thrombocytopenia [4]Blood and lymphatic system disorders | 17/23 | 60/67 | 10/12 | 72/89 |
| ChillsGeneral disorders | 15/23 | 52/67 | 9/12 | 64/89 |
| PyrexiaGeneral disorders | 9/23 | 39/67 | 6/12 | 42/89 |
| NauseaGastrointestinal disorders | 13/23 | 16/67 | 2/12 | 21/89 |
| Neutropenia [3]Blood and lymphatic system disorders | 11/23 | 37/67 | 5/12 | 30/89 |
| Leukopenia [1]Blood and lymphatic system disorders | 12/23 | 28/67 | 2/12 | 29/89 |
| TachycardiaCardiac disorders | 3/23 | 23/67 | 6/12 | 22/89 |
| Febrile neutropeniaBlood and lymphatic system disorders | 11/23 | 30/67 | 5/12 | 27/89 |
| HypophosphataemiaMetabolism and nutrition disorders | 6/23 | 30/67 | 5/12 | 28/89 |
The Safety Analysis Set is defined as patients who received the lifileucel infusion. Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Initial Treatment — <=18 years | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Between 18 and 65 years | 21 | 53 | 0 | 66 | 140 |
| Initial Treatment — >=65 years | 2 | 14 | 0 | 23 | 39 |
| Retreatment — <=18 years | — | — | 0 | — | 0 |
| Retreatment — Between 18 and 65 years | — | — | 11 | — | 11 |
| Retreatment — >=65 years | — | — | 1 | — | 1 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Initial Treatment | 52 (37 to 72) | 55 (20 to 79) | — | 58 (25 to 74) | 56 (20 to 79) |
| Retreatment | — | — | 52 (29 to 66) | — | 52 (29 to 66) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Initial Treatment — Female | 12 | 28 | 0 | 44 | 84 |
| Initial Treatment — Male | 11 | 39 | 0 | 45 | 95 |
| Retreatment — Female | 0 | 0 | 3 | 0 | 3 |
| Retreatment — Male | 0 | 0 | 9 | 0 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Initial Treatment — Hispanic or Latino | 2 | 5 | 0 | 3 | 10 |
| Initial Treatment — Not Hispanic or Latino | 21 | 55 | 0 | 85 | 161 |
| Initial Treatment — Unknown or Not Reported | 0 | 7 | 0 | 1 | 8 |
| Retreatment — Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Retreatment — Not Hispanic or Latino | 0 | 0 | 10 | 0 | 10 |
| Retreatment — Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Initial Treatment — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Asian | 0 | 2 | 0 | 1 | 3 |
| Initial Treatment — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Black or African American | 0 | 1 | 0 | 2 | 3 |
| Initial Treatment — White | 23 | 64 | 0 | 85 | 172 |
| Initial Treatment — More than one race | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Retreatment — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Asian | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Black or African American | 0 | 0 | 2 | 0 | 2 |
| Retreatment — White | 0 | 0 | 9 | 0 | 9 |
| Retreatment — More than one race | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| United States | 23 | 56 | 0 | 55 | 134 |
| France | 0 | 2 | 0 | 1 | 3 |
| Germany | 0 | 0 | 0 | 19 | 19 |
| Hungary | 0 | 2 | 0 | 0 | 2 |
| Spain | 0 | 3 | 0 | 10 | 13 |
| Switzerland | 0 | 1 | 0 | 0 | 1 |
| United Kingdom | 0 | 3 | 0 | 4 | 7 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| United States | 0 | 0 | 8 | 0 | 8 |
| France | 0 | 0 | 1 | 0 | 1 |
| Germany | 0 | 0 | 2 | 0 | 2 |
| United Kingdom | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2015 to primary completion in Oct 2024, 109 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 109 months is above that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lifileucel
Iovance Biotherapeutics, Inc.